We observed that the combination of both biomarkers resulted in excellent diagnostic accuracy only among BCLC‐C patients (AUROC 90.5%), a finding which suggests that serum PIVKA‐II levels might be less useful for HCC diagnosis in early stages in patients with cirrhotic background who do not express high serum AFP levels. Here, AFP is linked to hepatocellular carcinoma.